Real-world evidence shows comparable survival outcomes for triplet and doublet therapies in BRAF-mutated metastatic colorectal cancer, suggesting effectiveness of these treatments.
In real-world clinical practice, triplet and doublet therapies showed comparable survival outcomes, consistent with the BEACON trial. Triplet therapy may provide potential clinical benefit in patients with poor PFs.
No takes yet. Share an insight, caveat, or question.
Kotani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: